[Recurrent ataxia and respiratory failure with probable paraneoplastic syndrome responsive to plasma exchange therapy]

Rinsho Shinkeigaku. 2019 Jun 22;59(6):339-344. doi: 10.5692/clinicalneurol.cn-001234. Epub 2019 May 29.
[Article in Japanese]

Abstract

An 80-year-old male with prostatic adenocarcinoma who was treated with orchiectomy presented dysarthria and difficulty in walking. His symptoms subacutely progressed. Seven days later, he was non-ambulatory and was admitted to our hospital. He had poor vision and cerebellar ataxia of the lower extremities; however, his muscle strength, tendon reflexes, and sensory functions were preserved. Paraneoplastic retinopathy was diagnosed based on electroretinographic and visual field defect. Further, brain and spinal MRI, cerebral spinal fluid, and nerve conduction assessments were normal. These symptoms were followed by consciousness disturbance and respiratory failure; consequently, he required non-invasive positive pressure ventilation (NPPV) and tube feeding. Steroid pulse therapy and plasma exchange (PE) were performed. In response to the therapy, all these symptoms were relieved, and NPPV and tube feeding were withdrawn. However, the same symptoms occurred additional three times throughout the course of approximately 1 year. Each time, PE was the most effective treatment. Although paraneoplastic neurological syndrome associated with prostatic cancer is rare, immunotherapy could be a therapeutic choice to relive symptoms.

Keywords: paraneoplastic neurological syndrome; plasma exchange therapy; prostate adenocarcinoma; subacute cerebellar degeneration.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma
  • Aged, 80 and over
  • Cerebellar Ataxia / therapy*
  • Fatal Outcome
  • Humans
  • Male
  • Methylprednisolone / administration & dosage
  • Paraneoplastic Syndromes / therapy*
  • Plasma Exchange*
  • Prostatic Neoplasms
  • Pulse Therapy, Drug
  • Recurrence
  • Respiratory Insufficiency / therapy*
  • Treatment Outcome

Substances

  • Methylprednisolone